Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma
- Resource Type
- Article
- Source
- In
Blood Advances 23 January 2024 8(2):484-496 - Subject
Gene Therapy Lymphoid Neoplasia - Language
- ISSN
- 2473-9529